The COST Action ADVANCE-TB (Towards an improvement in diagnostics and treatment strategies for tuberculosis control) has concluded after four years of activity. The initiative, coordinated by Alicia Lacoma, a researcher at IGTP and CIBERES, has brought together over 280 professionals from 47 countries to share knowledge, develop common resources and methodologies, and foster new collaborations to improve the diagnosis, treatment, and monitoring of tuberculosis.
Although tuberculosis is a preventable and curable infectious disease, the World Health Organization estimates that in 2024, approximately 10.7 million cases and 1.23 million deaths occurred worldwide. Challenges such as antibiotic resistance and difficulties in detecting certain forms of the infection still hinder its control.
In this context, ADVANCE-TB was launched in September 2022 with the aim of bridging basic research with clinical practice, facilitating interdisciplinary cooperation, and promoting the development and evaluation of new diagnostic tools and therapeutic strategies. The Action has been funded by the European COST program (European Cooperation in Science and Technology).
The network has driven the development of shared tools and resources, such as the ADVANCE-TB Clinical Studies Platform, a network of clinical centers for multicenter studies with a database managed by IGTP using REDCap. Shared protocols for the collection and processing of clinical samples have also been developed, along with a database of compounds with antimycobacterial activity, and work has been done on evaluating new drugs and researching biomarkers.
The joint work has resulted in scientific publications, reviews, and consensus documents on various aspects of tuberculosis. Collaborations have generated proposals for joint projects, four of which have received funding, including two led by IGTP: TB-SPECTRUM, coordinated by Irene Latorre, and TBpreparedness4Ukraine, which has enabled Andrii Dudnyk to study drug resistance in antituberculosis drugs in samples from Ukraine.
ADVANCE-TB continues the trajectory of international cooperation initiated with previous projects such as INNOVA4TB, also coordinated by IGTP.
Over the four years, ADVANCE-TB has organized 49 activities, including scientific meetings, workshops, and debate sessions. 51% of the members were early-career researchers, and 58 grants were awarded, including 24 short-term research stays, fostering skill acquisition and knowledge exchange.
Despite the conclusion of COST funding, there are plans to maintain activities and resources such as the clinical studies platform and the database of antimycobacterial compounds to support future research. Periodic scientific sessions will continue with new initiatives like TB-SPECTRUM.




